DARE Quote, Financials, Valuation and Earnings

GeoVax Labs, Inc. has a net margin of -154904.35% compared to Daré Bioscience, Inc.'s net margin of -630.04%. Daré Bioscience, Inc.'s return on equity of -- beat GeoVax Labs, Inc.'s return on equity of -433.69%.

Daré Bioscience, Inc. has a consensus price target of $10.75, signalling upside risk potential of 395.39%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 5197.19%. Given that GeoVax Labs, Inc. has higher upside potential than Daré Bioscience, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Daré Bioscience, Inc..

Daré Bioscience, Inc. has a beta of 0.771, which suggesting that the stock is 22.917% less volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.638, suggesting its more volatile than the S&P 500 by 263.848%.

Daré Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daré Bioscience, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.

Daré Bioscience, Inc. quarterly revenues are $2.3K, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Daré Bioscience, Inc.'s net income of -$3.6M is higher than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Daré Bioscience, Inc.'s price-to-earnings ratio is 95.38x while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daré Bioscience, Inc. is 438.05x versus 0.79x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Omeros Corp. has a net margin of -154904.35% compared to Daré Bioscience, Inc.'s net margin of --. Daré Bioscience, Inc.'s return on equity of -- beat Omeros Corp.'s return on equity of --.

Daré Bioscience, Inc. has a consensus price target of $10.75, signalling upside risk potential of 395.39%. On the other hand Omeros Corp. has an analysts' consensus of $28.00 which suggests that it could grow by 82.29%. Given that Daré Bioscience, Inc. has higher upside potential than Omeros Corp., analysts believe Daré Bioscience, Inc. is more attractive than Omeros Corp..

Daré Bioscience, Inc. has a beta of 0.771, which suggesting that the stock is 22.917% less volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.485, suggesting its more volatile than the S&P 500 by 148.518%.

Daré Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daré Bioscience, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.

Daré Bioscience, Inc. quarterly revenues are $2.3K, which are larger than Omeros Corp. quarterly revenues of --. Daré Bioscience, Inc.'s net income of -$3.6M is higher than Omeros Corp.'s net income of -$21.2M. Notably, Daré Bioscience, Inc.'s price-to-earnings ratio is 95.38x while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daré Bioscience, Inc. is 438.05x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics, Inc. has a net margin of -154904.35% compared to Daré Bioscience, Inc.'s net margin of -242.19%. Daré Bioscience, Inc.'s return on equity of -- beat Spero Therapeutics, Inc.'s return on equity of -107.04%.

Daré Bioscience, Inc. has a consensus price target of $10.75, signalling upside risk potential of 395.39%. On the other hand Spero Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 70.94%. Given that Daré Bioscience, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Spero Therapeutics, Inc..

Daré Bioscience, Inc. has a beta of 0.771, which suggesting that the stock is 22.917% less volatile than S&P 500. In comparison Spero Therapeutics, Inc. has a beta of 1.482, suggesting its more volatile than the S&P 500 by 48.19%.

Daré Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daré Bioscience, Inc. pays -- of its earnings as a dividend. Spero Therapeutics, Inc. pays out -- of its earnings as a dividend.

Daré Bioscience, Inc. quarterly revenues are $2.3K, which are smaller than Spero Therapeutics, Inc. quarterly revenues of $3M. Daré Bioscience, Inc.'s net income of -$3.6M is higher than Spero Therapeutics, Inc.'s net income of -$7.4M. Notably, Daré Bioscience, Inc.'s price-to-earnings ratio is 95.38x while Spero Therapeutics, Inc.'s PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daré Bioscience, Inc. is 438.05x versus 4.43x for Spero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics, Inc. has a net margin of -154904.35% compared to Daré Bioscience, Inc.'s net margin of -7525.97%. Daré Bioscience, Inc.'s return on equity of -- beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.

Daré Bioscience, Inc. has a consensus price target of $10.75, signalling upside risk potential of 395.39%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 32.8%. Given that Daré Bioscience, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Vistagen Therapeutics, Inc..

Daré Bioscience, Inc. has a beta of 0.771, which suggesting that the stock is 22.917% less volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.86%.

Daré Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daré Bioscience, Inc. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.

Daré Bioscience, Inc. quarterly revenues are $2.3K, which are smaller than Vistagen Therapeutics, Inc. quarterly revenues of $258K. Daré Bioscience, Inc.'s net income of -$3.6M is higher than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, Daré Bioscience, Inc.'s price-to-earnings ratio is 95.38x while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daré Bioscience, Inc. is 438.05x versus 25.55x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.